Plain-English translation of NCT06241612 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Nasopharyngeal cancer often spreads to lymph nodes in the neck, and standard treatment involves radiation to a large area of the neck to prevent cancer from returning. This trial is testing a new, more targeted approach: using imaging scans to identify exactly which lymph nodes have cancer, then customizing the radiation treatment to focus only on those specific areas and nearby regions most likely to be affected. The goal is to achieve the same cancer control and survival rates while reducing uncomfortable side effects like difficulty swallowing, fatigue, and thyroid damage.
Previous research showed that narrowing the radiation field from the whole neck to just the upper neck reduced serious side effects without harming survival. This trial takes that a step further by using a detailed pattern doctors have discovered—that cancer tends to spread downward along the spine in a predictable way—to make radiation treatment even more precise and personalized to each patient's specific situation.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to one of two groups: one receiving standard upper-neck radiation therapy, or one receiving the new personalized, more narrowly focused radiation therapy based on your individual lymph node pattern. Both groups will receive the same chemotherapy and follow the same treatment schedule. You will have regular clinic visits for imaging scans, blood tests, and check-ups to monitor how well the treatment is working and to track any side effects during and after your radiation therapy.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Sun Yat-sen University
Collaborators
First People's Hospital of Foshan, Sichuan Cancer Hospital and Research Institute
Enrollment target
~470 participants
Started
April 2024
Primary completion
December 2026
Age range
18 Years – 70 Years
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Ling-Long Tang, Prof
Sun Yat-sen University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.